Are T2 biomarkers of any help in diagnosing asthma? Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020
The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017
The challenge of getting the right diagnosis: asthma and COPD, new diagnostic possibilities Source: International Congress 2016 – Primary Care Day: challenging times I Year: 2016
The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity Source: Eur Respir J, 52 (5) 1800694; 10.1183/13993003.00694-2018 Year: 2018
Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho Source: Eur Respir J 2014; 43: 322-324 Year: 2013
Robust prediction of later asthma in symptomatic toddlers: A novel approach Source: Annual Congress 2011 - Paediatric epidemiology: predicting outcomes of wheeze, antenatal growth, early life exposures and outcome of premature birth Year: 2011
A new perspective on concepts of asthma severity, control and optimum treatment Source: Eur Respir J 2009; 33: 704-705 Year: 2009
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020
COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging Source: Eur Respir J, 52 (5) 1801570; 10.1183/13993003.01570-2018 Year: 2018
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
Emerging biologic approaches for the treatment of difficult to control asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017
Z-alpha1-antitrypsin polymers and small airways disease: a new paradigm in COPD development? Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020
Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019
The quest for the grail: multidimensional efforts for understanding and targeting severe asthma Source: Eur Respir J 2015; 46: 1227-1231 Year: 2015
Features of asthma management: quantifying the patient‘s perspective using discrete choice modelling Source: Eur Respir J 2006; 28: Suppl. 50, 122s Year: 2006
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016
Adding biological markers to COPD categorisation schemes: a way towards more personalised care? Source: Eur Respir J 2016; 47:1601-1605 Year: 2016
Do we need new asthma control tests? Source: Eur Respir J 2014; 44: 1116-1118 Year: 2014
“To define is to limit”: perspectives on asthma–COPD overlap syndrome and personalised medicine Source: Eur Respir J, 49 (5) 1700336; 10.1183/13993003.00336-2017 Year: 2017